Moderna

We just announced that we have entered into an agreement for @baxter_intl to provide fill/finish sterile manufactur… https://t.co/shZVc4EwnM

We are delighted to share that Shannon Thyme Klinger will join Moderna as Chief Legal Officer effective June 1. Rea… https://t.co/xoL3npqj78

Earlier today, we announced a supply agreement to provide 13 million doses of COVID-19 Vaccine Moderna to the Phili… https://t.co/Nxo156TrPn

We just announced that @TakedaPharma has submitted a New Drug Application to the Government of Japan’s Ministry of… https://t.co/Vfhhs5H5fu

Cytomegalovirus , or #CMV is a silent virus that few people know about. This virus is the number 1 infectious cause of birth defects in the US. Learn more here: https:// www.stopcmvsilen ce.com/ #StopCMV #CMVawareness

Learn more at https://t.co/m2ATNzooSu https://t.co/MeVN9qK9mq

View the #ESMOTAT21 presentation slides here: https://t.co/OhFSg9HSsH https://t.co/Sa9I3Mrp7z

Hear from Ruchira Glaser, M.D., M.S., our SVP, Therapeutic Area Head, Rare Disease, Autoimmune & Cardiovascular, on the strides we've made to build the Moderna team, renew our focus on #RareDisease & strengthen our science & study designs: https:// buff.ly/303ecxK

We are proud to show our stripes in support of Rare Disease Day! #RareDiseaseDay2 021 #ShowYourStripes

The Phase 2/3 “TeenCOVE” study of mRNA-1273 in adolescents ages 12-17 yrs completed enrollment of 3,000 participants. The Phase 2 “KidCOVE” study of mRNA-1273 in the pediatric population ages 6 months to 11 yrs will start in the near-term: https:// buff.ly/3aR6CfD